TY  - JOUR
AU  - Ruiz-Villaverde, R
AU  - Rodríguez Fernández-Freire, L
AU  - Galán-Gutiérrez, M
AU  - Armario-Hita, J C
AU  - Martinez-Pilar, L
PY  - 2020
DO  - 10.1016/j.ad.2019.05.018
UR  - http://hdl.handle.net/10668/16513
T2  - Actas dermo-sifiliograficas
AB  - Secukinumab, an immunoglobulin G1/κ monoclonal antibody that selectively targets interleukin 17a, is used to treat moderate to severe plaque psoriasis in adults who are eligible for systemic treatment. Indirect comparisons of the efficacy of...
LA  - en
KW  - Drug survival
KW  - Psoriasis
KW  - Secukinumab
KW  - Supervivencia
KW  - Adult
KW  - Antibodies, Monoclonal, Humanized
KW  - Humans
KW  - Pharmaceutical Preparations
KW  - Retrospective Studies
KW  - Severity of Illness Index
TI  - Secukinumab: Drug Survival in Clinical Practice Settings.
T2  - Secukinumab: supervivencia en práctica clínica real.
TY  - research article
VL  - 112
ER  -